Increases BDNF and NGF in hippocampus; activates dopaminergic and serotonergic systems; melanocortin receptor activity.
Reference facts
- Also known as
- MEHFPGP, ACTH (4-7) Pro-Gly-Pro
- Category
- Nootropic & Cognitive
- Mechanism of action
- Increases BDNF and NGF in hippocampus; activates dopaminergic and serotonergic systems; melanocortin receptor activity.
- Targets
- BDNF/NGF up-regulation, Melanocortin receptors
- Indications under research or approved
- Approved Russia (ischemic stroke, cognitive disorders); not US-approved
- Regulatory status (reference entry)
- Not FDA-approved
- Half-life
- ~30 minutes (intranasal)
- Sequence
- MEHFPGP
- Sequence notes
- Heptapeptide. ACTH (4-7) fragment Met-Glu-His-Phe extended with the proline-glycine-proline tail used in Russian peptide design to resist enzymatic degradation.
- Molecular weight (Da)
- 813
- First reported
- 1981
Primary References
Explore research articles about Semax
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.